Literature DB >> 19956439

AKT and PTEN expression in human gastrointestinal carcinoid tumors.

Susan C Pitt1, Ruth Davis, Muthusamy Kunnimalaiyaan, Herbert Chen.   

Abstract

Activation of Akt (protein kinase B) and loss of phosphatase and tensin homolog (PTEN) expression have been associated with disease recurrence and reduced survival in several cancers. We evaluated the expression patterns and prognostic value of active, phosphorylated Akt (pAkt) and PTEN in gastrointestinal (GI) carcinoid tumors. Total Akt, pAkt, and PTEN expression was assessed by Western blot analysis in 14 tumor samples from patients with GI carcinoid tumors. Expression levels were quantified with volume analysis software and correlated with clinical parameters. Total Akt, pAkt, and PTEN proteins were detectable in all tumor samples. The expression of activated pAkt and pAkt:PTEN ratios were significantly associated with elevated serum chromogranin A measurements (r=0.77 and 0.78, respectively, P</=0.02 for both). In addition, pAkt:PTEN expression ratios positively correlated with older age (r=0.65, P=0.017). Increased pAkt and pAkt:PTEN expression both were associated with reduced survival (r= -0.51, P=0.06 and r= -0.50, P=0.09, respectively). Patients with pAkt:PTEN ratios greater than one also had dramatically reduced overall survival, but this finding did not achieve statistical significance (36 vs. 153 months, P=0.19). These data suggest that pAkt and PTEN expression levels may be useful tools in understanding tumor biology and perhaps predicting survival in patients with carcinoid tumors. Furthermore, cumulative mutations may lead to upregulation of pAkt and loss of PTEN expression as patients age explaining why older age is associated with a worse prognosis in patients with carcinoid tumors.

Entities:  

Keywords:  Akt; Carcinoid tumors; PTEN; chromogranin A; survival

Year:  2009        PMID: 19956439      PMCID: PMC2776321     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  25 in total

1.  Epidermal growth factor receptor expression and activation in neuroendocrine tumours.

Authors:  T Shah; D Hochhauser; R Frow; A Quaglia; A P Dhillon; M E Caplin
Journal:  J Neuroendocrinol       Date:  2006-05       Impact factor: 3.627

2.  Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma.

Authors:  Y Kanamori; J Kigawa; H Itamochi; M Shimada; M Takahashi; S Kamazawa; S Sato; R Akeshima; N Terakawa
Journal:  Clin Cancer Res       Date:  2001-04       Impact factor: 12.531

3.  AKT activation predicts outcome in breast cancer patients treated with tamoxifen.

Authors:  Tove Kirkegaard; Caroline J Witton; Liane M McGlynn; Sian M Tovey; Barbara Dunne; Alison Lyon; John M S Bartlett
Journal:  J Pathol       Date:  2005-10       Impact factor: 7.996

Review 4.  The molecular genetics of gastroenteropancreatic neuroendocrine tumors.

Authors:  Michelle N Zikusoka; Mark Kidd; Geeta Eick; Igor Latich; Irvin M Modlin
Journal:  Cancer       Date:  2005-12-01       Impact factor: 6.860

5.  Apoptosis-mediated medullary thyroid cancer growth suppression by the PI3K inhibitor LY294002.

Authors:  Muthusamy Kunnimalaiyaan; Mary Ndiaye; Herbert Chen
Journal:  Surgery       Date:  2006-11-01       Impact factor: 3.982

6.  Expression of phosphorylated Akt (pAkt) in gastric carcinoma predicts prognosis and efficacy of chemotherapy.

Authors:  Daiki Murakami; Shunichi Tsujitani; Tomohiro Osaki; Hiroaki Saito; Kuniyuki Katano; Shigeru Tatebe; Masahide Ikeguchi
Journal:  Gastric Cancer       Date:  2007-02-23       Impact factor: 7.370

7.  Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection.

Authors:  Klaus Juergen Schmitz; Jeremias Wohlschlaeger; Hauke Lang; Georgios Charalambos Sotiropoulos; Massimo Malago; Karen Steveling; Henning Reis; Vito Rosario Cicinnati; Kurt Werner Schmid; Hideo Andreas Baba
Journal:  J Hepatol       Date:  2007-10-29       Impact factor: 25.083

8.  Activation of PI3K is associated with reduced survival in renal cell carcinoma.

Authors:  Axel S Merseburger; Joerg Hennenlotter; Ursula Kuehs; Perikles Simon; Stephan Kruck; Eva Koch; Arnulf Stenzl; Markus A Kuczyk
Journal:  Urol Int       Date:  2008-06-27       Impact factor: 2.089

9.  Clinicopathological significance of PTEN loss and the phosphoinositide 3-kinase/Akt pathway in sporadic colorectal neoplasms: is PTEN loss predictor of local recurrence?

Authors:  Tamer Colakoglu; Sedat Yildirim; Fazilet Kayaselcuk; Tarik Zafer Nursal; Ali Ezer; Turgut Noyan; Hamdi Karakayali; Mehmet Haberal
Journal:  Am J Surg       Date:  2008-04-28       Impact factor: 2.565

10.  Activated Akt as an indicator of prognosis in gastric cancer.

Authors:  Caterina Cinti; Carla Vindigni; Alessandra Zamparelli; Dario La Sala; Maria Carmela Epistolato; Daniele Marrelli; Gabriele Cevenini; Piero Tosi
Journal:  Virchows Arch       Date:  2008-10-08       Impact factor: 4.064

View more
  10 in total

1.  Cotargeting the PI3K and RAS pathways for the treatment of neuroendocrine tumors.

Authors:  Joseph D Valentino; Jing Li; Yekaterina Y Zaytseva; W Conan Mustain; Victoria A Elliott; Ji Tae Kim; Jennifer W Harris; Katherine Campbell; Heidi Weiss; Chi Wang; Jun Song; Lowell Anthony; Courtney M Townsend; B Mark Evers
Journal:  Clin Cancer Res       Date:  2014-01-17       Impact factor: 12.531

Review 2.  Signaling pathways as specific pharmacologic targets for neuroendocrine tumor therapy: RET, PI3K, MEK, growth factors, and Notch.

Authors:  Yvette Carter; Renata Jaskula-Sztul; Herbert Chen; Haggi Mazeh
Journal:  Neuroendocrinology       Date:  2012-02-14       Impact factor: 4.914

3.  Neuroendocrine phenotype alteration and growth suppression through apoptosis by MK-2206, an allosteric inhibitor of AKT, in carcinoid cell lines in vitro.

Authors:  Yash Somnay; Kevin Simon; April D Harrison; Selvi Kunnimalaiyaan; Herbert Chen; Muthusamy Kunnimalaiyaan
Journal:  Anticancer Drugs       Date:  2013-01       Impact factor: 2.248

Review 4.  The Phosphatidylinositol 3-kinase/Akt Signaling Pathway in Neuroendocrine Tumors.

Authors:  Yash R Somnay; Muthusamy Kunnimalaiyaan
Journal:  Glob J Biochem       Date:  2011-03-08

5.  The effect of PTEN on serotonin synthesis and secretion from the carcinoid cell line BON.

Authors:  Scott R Silva; Yekaterina Y Zaytseva; Lindsey N Jackson; Eun Y Lee; Heidi L Weiss; Kanika A Bowen; Courtney M Townsend; B Mark Evers
Journal:  Anticancer Res       Date:  2011-04       Impact factor: 2.480

Review 6.  New pharmacologic therapies for gastroenteropancreatic neuroendocrine tumors.

Authors:  Ben Lawrence; Bjorn I Gustafsson; Mark Kidd; Irvin Modlin
Journal:  Gastroenterol Clin North Am       Date:  2010-09       Impact factor: 3.806

7.  Pulmonary atypical carcinoid in a patient with Cowden syndrome.

Authors:  Hiroaki Tsunezuka; Kaori Abe; Junichi Shimada; Masayoshi Inoue
Journal:  Interact Cardiovasc Thorac Surg       Date:  2016-02-29

8.  Abnormal activation of the Akt signaling pathway in adenoid cystic carcinoma.

Authors:  Karla Flaviana Carneiro Castelo Branco; Andre Luis Ribeiro Ribeiro; Raíssa Pinheiro de Mendonça; João de Jesus Viana Pinheiro; Maria Sueli da Silva Kataoka; Maria Vanda Catão Arnaud; Sérgio de Melo Alves Junior
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-10-26       Impact factor: 2.503

Review 9.  Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets.

Authors:  E T Aristizabal Prada; C J Auernhammer
Journal:  Endocr Connect       Date:  2017-11-16       Impact factor: 3.335

10.  The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models.

Authors:  Svenja Nölting; Jakob Rentsch; Helma Freitag; Katharina Detjen; Franziska Briest; Markus Möbs; Victoria Weissmann; Britta Siegmund; Christoph J Auernhammer; Elke Tatjana Aristizabal Prada; Michael Lauseker; Ashley Grossman; Samantha Exner; Christian Fischer; Carsten Grötzinger; Jörg Schrader; Patricia Grabowski
Journal:  PLoS One       Date:  2017-08-11       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.